Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;174(10):1404-1408.
doi: 10.7326/M21-1577. Epub 2021 Jul 20.

SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

Adeel A Butt  1 , Saad B Omer  2 , Peng Yan  3 , Obaid S Shaikh  4 , Florian B Mayr  5
Affiliations

SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

Adeel A Butt et al. Ann Intern Med. 2021 Oct.

Abstract

Background: With the emergency use authorization of multiple vaccines against SARS-CoV-2 infection, data are urgently needed to determine their effectiveness in a real-world setting.

Objective: To evaluate the short-term effectiveness of vaccines in preventing SARS-CoV-2 infection.

Design: Test-negative case-control study using conditional logistic regression.

Setting: U.S. Department of Veterans Affairs health care system.

Participants: All veterans who had testing for SARS-CoV-2 infection between 15 December 2020 and 4 March 2021 and no confirmed infection before 15 December 2020.

Intervention: SARS-CoV-2 vaccination with either the BNT-162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine as part of routine clinical care.

Measurements: Effectiveness of vaccination against confirmed SARS-CoV-2 infection.

Results: Among 54 360 persons who tested positive and 54 360 propensity score-matched control participants, the median age was 61 years, 83.6% were male, and 62% were White. Median body mass index was 31 kg/m2 among those who tested positive and 30 kg/m2 among those who tested negative. Among those who tested positive, 9800 (18.0%) had been vaccinated; among those who tested negative, 17 825 (32.8%) had been vaccinated. Overall vaccine effectiveness 7 or more days after the second dose was 97.1% (95% CI, 96.6% to 97.5%). Effectiveness was 96.2% (CI, 95.5% to 96.9%) for the Pfizer-BioNTech BNT-162b2 vaccine and 98.2% (CI, 97.5% to 98.6%) for the Moderna mRNA-1273 vaccine. Effectiveness remained above 95% regardless of age group, sex, race, or presence of comorbidities.

Limitations: Predominantly male population; lack of data on disease severity, mortality, and effectiveness by SARS-CoV-2 variants of concern; and short-term follow-up.

Conclusion: Currently used vaccines against SARS-CoV-2 infection are highly effective in preventing confirmed infection in a high-risk population in a real-world setting.

Primary funding source: None.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-1577.

Figures

Visual Abstract.
Visual Abstract.. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population.
Data are urgently needed on the real-world effectiveness of the currently administered COVID-19 vaccines. This case–control study evaluated the short-term effectiveness of currently administered vaccines in preventing confirmed SARS-CoV-2 infection among veterans receiving care in the U.S. Department of Veterans Affairs health care system.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baden LR , El Sahly HM , Essink B , et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-16. [PMID: ] doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP , Thomas SJ , Kitchin N , et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-15. [PMID: ] doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Dagan N , Barda N , Kepten E , et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-23. [PMID: ] doi:10.1056/NEJMoa2101765 - DOI - PMC - PubMed
    1. Abu-Raddad LJ , Chemaitelly H , Butt AA ; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants [Letter]. N Engl J Med. 2021. [PMID: ] doi:10.1056/NEJMc2104974 - DOI - PMC - PubMed
    1. Keehner J , Horton LE , Pfeffer MA , et al. SARS-CoV-2 infection after vaccination in health care workers in California [Letter]. N Engl J Med. 2021;384:1774-5. [PMID: ] doi:10.1056/NEJMc2101927 - DOI - PMC - PubMed